QIAGEN N.V. — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing; the filing does not provide a clear Q4-only financial summary. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Business context and financial performance
QIAGEN provides molecular testing and research products, instruments, and bioinformatics solutions to customers in Molecular Diagnostics and Life Sciences. FY2022 net sales were $2.142 billion, down 5% from $2.252 billion in 2021. Growth in non-COVID product groups was more than offset by lower COVID-19 testing demand; unfavorable currency movements reduced reported results by approximately five percentage points.
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net sales | $2,141.5 million | $2,251.7 million |
| Gross profit / margin | $1,384.6 million / 64.7% | $1,450.8 million / 64.4% |
| Operating income / margin | $531.5 million / 24.8% | $630.1 million / 28.0% |
| Net income | $423.2 million | $512.6 million |
| Diluted EPS | $1.84 | $2.21 |
| Cash from operations | $715.3 million | $639.0 million |
Gross margin edged higher despite product mix and cost pressures. Operating income fell 16%, as operating expenses rose to 39.8% of sales from 36.5%, including higher commercialization, capacity-expansion, restructuring and integration costs. The effective tax rate was 17.4%, versus 18.1%.
Sales by customer class were $1.126 billion in Molecular Diagnostics, down 2%, and $1.015 billion in Life Sciences, down 8%. Diagnostic Solutions grew 3% to $660.9 million, including 17% growth in QuantiFERON-TB. Sample Technologies declined 6%, PCR/Nucleic Acid Amplification declined 10%, and Genomics/NGS declined 8%.
Cash, liquidity and debt
Cash and cash equivalents were $730.7 million and short-term investments were $687.6 million at year-end, totaling $1.418 billion, up from $1.065 billion. Working capital was $1.419 billion, compared with $592.1 million. Operating cash flow was $715.3 million; investing activities used $726.8 million, mainly reflecting net short-term investment purchases, and financing activities used $125.8 million.
Long-term debt had a carrying value of $1.861 billion, of which $389.6 million was current and due in 2023. The company repaid $480.0 million of long-term debt and issued $371.5 million through a euro-denominated private placement in 2022. Undrawn credit facilities totaled approximately $455 million; none were used at year-end. Management said operating cash flow, cash on hand and available financing were expected to fund planned operations and expansion in the coming year. QIAGEN has no credit rating and does not intend to pay dividends in the foreseeable future.
Changes, outlook and notable items
- Outlook: The February 2023 outlook anticipated continued solid growth in non-COVID product groups but a significant further decline in COVID-19 sales, implying overall sales below FY2022. EPS was expected to be below FY2022, reflecting lower sales and investment to support growth. Currency was expected to be broadly neutral for the full year, with an adverse first-half impact. The outlook excluded potential acquisitions.
- Costs and impairments: Restructuring, acquisition, integration and other expenses were $44.8 million, versus $27.8 million in 2021. The company recorded a $12.8 million impairment of its Ellume technology license and $4.0 million of credit losses, write-offs and impairments related to Russia. A fourth-quarter restructuring plan to discontinue third-party instrument servicing and realign management was expected to cost about $8 million in total, with approximately $3 million remaining for 2023.
- Acquisitions: QIAGEN acquired BLIRT for $63.7 million net cash in 2022. On January 3, 2023, it acquired Verogen for $150 million, subject to adjustment.
- Geopolitical and operating risks: QIAGEN suspended operations in Russia and Belarus; sales in Russia, Belarus and Ukraine had represented less than 1% of annual sales. Management expected some supply constraints to continue in 2023 amid inflation, higher input and logistics costs, and geopolitical uncertainty.
- Other risks and contingencies: Key risks include product-development and regulatory delays, competition and customer adoption, reimbursement and research-funding changes, supplier concentration for certain components, cybersecurity and privacy, foreign-exchange volatility, and acquisition integration. Unrecognized tax benefits were $79.3 million. Other litigation accruals were $6.5 million, with estimated possible losses of up to $8 million; the company also reported a $4.7 million accrual related to the ArcherDX patent verdict and planned to appeal.
- Audit and controls: The auditor gave unqualified opinions on the financial statements and the effectiveness of internal control over financial reporting as of December 31, 2022.
Key facts for investors to verify
- Whether non-COVID growth can offset the continued decline in COVID-related sales and deliver the stated 2023 outlook.
- How the 2023 debt maturity of $389.6 million is funded or refinanced, and how debt costs and covenants affect financial flexibility.
- Whether supply constraints, inflation, currency movements and commercialization spending pressure operating margins and cash flow.
- The resolution and cash impact of tax uncertainties, litigation, contingent acquisition payments and the remaining restructuring costs.
- Whether adoption of QIAstat-Dx, NeuMoDx and QIAcuity platforms and their associated consumables supports the expected longer-term growth strategy.